论文部分内容阅读
目的:探讨盐酸坦索罗辛单一药物治疗BPH首次尿潴留患者的临床效果。方法:选择因急性尿潴留前来治疗的BPH患者32例,用单一药物盐酸坦索罗辛按0.2 mg·次~(-1)·晚~(-1)使用1年,并留置导尿1周后拔除,观察其疗效及再次尿潴留情况。结果:国际前列腺症状评分(IPSS)由治疗前(20.5±4.4)分下降到(14.0±2.2)分,生活质量指数评分(QOL)由治疗前(4.3±1.4)分下降到(2.0±1.1)分;尿流率增加到(15.23±1.10)ml/min,剩余尿量减少到(37.6±13.2)ml,再次尿潴留发生率为9.38%(3/32);治疗期间未发现因并发症而停止用药。结论:盐酸坦索罗辛单一药物治疗首次尿潴留的BPH患者安全有效,可减少剩余尿量,降低再发尿潴留的风险,值得临床推广。
Objective: To investigate the clinical effect of tamsulosin hydrochloride monotherapy on the first urinary retention in BPH patients. Methods: Twenty-two BPH patients were selected for treatment of acute urinary retention. Patients were given tamsulosin hydrochloride at a dose of 0.2 mg · min -1 (-1) for 1 year and catheterized 1 Weeks after the removal, observe its efficacy and re-urinary retention. Results: The score of International Prostate Symptom Index (IPSS) decreased from (20.5 ± 4.4) points to (14.0 ± 2.2) points before treatment, and the QOL decreased from (4.3 ± 1.4) points before treatment to (2.0 ± 1.1) (15.23 ± 1.10) ml / min, the residual urine volume decreased to (37.6 ± 13.2) ml, and the incidence of re-urinary retention was 9.38% (3/32). No complications were found during the treatment Stop medication. Conclusion: Tamsulosin hydrochloride single-drug treatment of first-time urinary retention in patients with BPH is safe and effective, can reduce the residual urine volume and reduce the risk of recurrent urinary retention, worthy of clinical promotion.